Baidu
map

治疗甲亢危象 不仅要对症更要速度!

2018-01-19 王 绵 张力辉 殷立新 内分泌系统疾病

主诉 怕热、多汗、心悸2年,恶心、呕吐、腹痛、发热5天。

病例介绍

主诉 怕热、多汗、心悸2年,恶心、呕吐、腹痛、发热5天。

现病史 患者缘于2年前无明显诱因出现怕热、多汗、心悸,自觉体重明显下降(具体数值不详),伴手抖、乏力、脾气急躁,就诊于当地医院,诊断为甲亢,并开始口服甲巯咪唑治疗,具体剂量不详,一直未规律复查,近期甲巯咪唑用量为1次5mg,1日1次。5天前进食生冷食物后出现恶心、呕吐,呕吐物为胃内容物,伴腹痛、腹泻、发热,体温38.8℃,就诊于当地医院,查心电图示:窦性心动过速,心脏彩超示EF在正常范围,胸片示左肺结核,心肌酶增高,肌钙蛋白阴性,经治疗无好转(具体治疗不详)。2天前患者出现咳嗽、气短,去医院急诊,给予抗感染(盐酸左氧氟沙星)等治疗,恶心、呕吐、腹痛症状有所好转,仍有咳嗽、发热,体温最高达39.2℃,为进一步诊治而入院。患者发病以来,精神烦躁、睡眠差、食欲差,大、小便正常。

既往史 既往肺结核病史3年,曾予以口服药物治疗,已愈。无肝炎等其他传染性疾病史,无高血压、冠心病、糖尿病病史,无外伤手术史。预防接种史不详。

家族史 无家族性遗传病及传染病史。

个人史 吸烟史30年,30支/日,无饮酒史,无其他不良嗜好。

既往用药史 入院前曾行甲巯咪唑治疗,近期用量为1次5mg,1日1次。急诊曾应用盐酸左氧氟沙星静脉滴注。其余用药品种及剂量不详。

过敏史 无药物及食物过敏史。

【体格检查】

一般状况 男性,54岁,身高170c m,体重60kg,发育正常,营养一般。神志清楚,嗜睡,查体合作。

生命体征 T 39﹒2℃,P 146次/分,R 23次/分,BP 110/70 mmHg。

皮肤 全身皮肤黏膜轻度黄染,无皮下出血、皮疹,无肝掌及蜘蛛痣。全身浅表淋巴结未及肿大。

五官 头颅无畸形,轻度突眼,双眼上睑挛缩,睑裂增宽,眼睑无水肿,结膜无充血及苍白,巩膜轻度黄染,双侧瞳孔正大等圆,对光反射灵敏。耳鼻检查无异常。口唇无发绀。咽无充血,扁桃体无肿大。

颈部 颈两侧对称,无颈静脉怒张及颈动脉异常搏动。颈软,气管居中,甲状腺Ⅱ度肿大,质韧,无压痛,未闻及血管杂音。

胸部 胸廓对称,双侧呼吸动度一致,无皮下气肿,胸骨无压痛,触觉语颤均等,无增强或减弱,叩诊清音,肺肝浊音界位于右锁骨中线第Ⅴ肋间,双肺呼吸音粗,右下肺可闻及湿啰音,未闻及干性啰音。

心脏 心前区无隆起,触无震颤,心界不大,心率146次/分,第一心音增强,各瓣膜听诊区未闻及杂音。

腹部 腹部平坦,无腹壁静脉曲张,未见胃肠型及蠕动波。腹软,脐上有轻微压痛,无反跳痛、肌紧张,肝脾肋下未及。无异常包块。叩诊鼓音,移动性浊音阴性。肠鸣音正常。

四肢 脊柱、四肢无畸形,活动自如,双手震颤,双下肢无水肿。

神经系统 生理反射存在,双巴氏征阴性。脑膜刺激征阴性。

辅助检查

1﹒血常规 WBC 15﹒0 ×109/L,NE%86﹒1%,NEUT 12﹒9 ×109/L。

2﹒肝功能 ALT 73U/L,ALB 34﹒7g/L,TBIL 40﹒53μmol/L,DBIL 17﹒23μmol/L,IBIL 23﹒3μmol/L;心肌酶:CK 280U/L,CKMB 103﹒6U/L,LDH 551U/L,α‐HBDH 539﹒9U/L。

3﹒甲状腺功能 FT36﹒59p mol/L,FT460p mol/L,TSH 0﹒002μI U/ml,TPOAb 314U/ml,TGAb 297U/ml。

4﹒BNP 312pg/ml。

5﹒心电图 窦性心动过速(142次/分),Ⅱ、Ⅲ、avF、V4~V6导联ST段压低。

6﹒肺CT 左肺上叶硬结伴钙化、纤维条索形成,考虑继发型肺结核;两肺弥漫性肺气肿,以两肺上叶为著;两肺下叶弥漫性透亮度减低,考虑灌注不均;左心增大,主动脉及冠状动脉硬化;纵隔内多发肿大淋巴结影。

入院诊断

1﹒Graves病,甲亢 甲亢危象。

2﹒肺部感染

3﹒急性胃肠炎。

诊疗经过 入院后内科Ⅰ级护理,初始医嘱如下:

高热量、高维生素、低碘饮食

复合维生素B片2片tid po

盐酸普萘洛尔片10mg tid po

丙硫氧嘧啶片600mg立即口服;200mg q8h po

复方碘溶液5滴q6h po

氢化可的松注射液100mg +0.9%氯化钠注射液ivgtt q8h

注射用还原型谷胱甘肽1.2g +10%氯化钾注射液5ml +生物合成人胰岛素注射液3U +5%葡萄糖注射液250ml ivgtt qd

盐酸左氧氟沙星注射液0.5g +0.9%氯化钠注射液100ml ivgtt qd

注射用阿洛西林钠3.0g +0.9%氯化钠注射液100ml ivgtt bid

注射用盐酸氨溴索30mg +0.9%氯化钠注射液100 ml ivgtt q8h

复方甘草酸单铵注射液120mg +10%氯化钾注射液5 ml +生物合成人胰岛素注射液3U +5%葡萄糖注射液250ml ivgtt bid

甲状腺危象简称甲亢危象,表现为甲亢症状的急骤加重和恶化。诊断主要靠临床表现综合判断。甲亢患者如果出现高热或过高热、大汗、心动过速(140次/分以上)、烦躁、焦虑不案、谵妄、恶心、呕吐、腹泻甚至出现心力衰竭、休克及昏迷者考虑存在甲亢危象。该患者甲亢的症状重,近5天在感染存在的情况下,病情恶化,出现高热(体温达39.2℃)、心动过速(心率146次/分)、烦躁、恶心、呕吐等,因此考虑存在甲亢危象。

入院后立即治疗甲亢危象,首选丙硫氧嘧啶,不仅抑制甲状腺激素的合成,而且抑制T4向T3的转化,首剂600mg,然后改为200mg,每8小时口服1次,同时应用了糖皮质激素、碘剂,β受体阻断剂;抗感染治疗:肠道感染和呼吸道感染是患者发生甲亢危象的诱因,所以静脉给予盐酸左氧氟沙星及阿洛西林钠,积极控制感染,盐酸氨溴索化痰;还原型谷胱甘肽和复方甘草酸单铵抗氧化应激,保护肝细胞膜,促进肝细胞再生,保肝降黄治疗;盐酸普萘洛尔降低心室率。患者咳嗽、咳痰症状无明显好转,且有间断发热,考虑肺部感染未控制,将抗菌药盐酸左氧氟沙星及阿洛西林钠调整为头孢哌酮钠舒巴坦钠抗感染治疗,并加用多索茶碱舒张支气管治疗。治疗过程中患者出现了胸闷、气短,Ptfv1阳性,考虑心功能不全,将盐酸普萘洛尔片调整为富马酸比索洛尔。经治疗,症状缓解,肝功能恢复,感染控制,出院,院外继续应用丙硫氧嘧啶片抗甲状腺治疗。

出院诊断

1﹒Graves病,甲亢 ①甲亢危象;②甲亢性心脏病:心力衰竭。

2﹒肺炎。

3﹒急性胃肠炎。

病例特点与诊断要点

1﹒病史 2年前无明显诱因出现怕热、多汗、心悸,自觉体重明显下降(具体数值不详),伴手抖、乏力、脾气急躁,于当地医院,诊断为甲亢,并开始口服甲巯咪唑治疗。5天前进食生冷食物后出现恶心、呕吐,伴腹痛、发热,2天前患者出现咳嗽、气短。

2﹒血常规 WBC 15﹒0 ×109/L,NE%86﹒1%,NEUT 12﹒9 ×109/L。

3﹒肝功能 AST 73U/L,ALB 34﹒7g/L,TBIL 40﹒53μmol/L,DBIL 17﹒23μmol/L,IBIL 23﹒3μmol/L。

4﹒心肌酶 CK 280U/L,CKMB 103﹒6U/L,LDH 551U/L,α‐HBDH 539﹒9U/L。

5﹒甲状腺功能 FT36﹒59p mol/L,FT460p mol/L,TSH 0﹒002μIU/ml,TPOAb 314U/ml,TGAb 297U/ml。

6﹒BNP 312pg/ml。

7﹒心电图 窦性心动过速(142次/分),Ptfv1阳性,Ⅱ、Ⅲ、avF、V4~V6导联ST段压低。

8﹒肺CT 左肺上叶硬结伴钙化、纤维条索形成,考虑继发型肺结核;两肺弥漫性肺气肿,以两肺上叶为著;两肺下叶弥漫性透亮度减低,考虑灌注不均;左心增大,主动脉及冠状动脉硬化;纵隔内多发肿大淋巴结影。

用药分析与药学监护

1﹒甲亢危象的治疗

(1)抗甲状腺药物:

抑制甲状腺激素的合成。一旦确诊,应尽快进行。甲亢危象时首选丙硫氧嘧啶(PT U)治疗,PT U不仅可以抑制甲状腺激素的合成,而且还可抑制T4在外周组织中转换成生物活性更强的T3,以尽快改善患者症状,控制高甲状腺激素血症。PT U首次剂量600mg,口服或经胃管内注入,继之200mg,每8小时1次,症状好转后逐渐将剂量减至常规剂量。如无PT U时,可用等量MT U或MMI 60mg,继用PT U(或MT U)200mg或MMI 20mg,1日3次,口服。待症状减轻后改用一般治疗剂量。

(2)复方碘溶液:

抑制甲状腺激素的释放。在服首剂PTU后,1~2小时再加用复方碘溶液,首剂30~60滴,以后每6~8小时5~10滴。或用碘化钠0.5~1.0g加入5%葡萄糖氯化钠注射液中,静脉滴注12~24小时,以后视病情逐渐减量,一般使用3~7天后停药。如患者对碘剂过敏,可改用碳酸锂0.5~1.0g/d,分3次口服,连服3~7天。

(3)β受体阻断剂:

普萘洛尔可以控制交感神经兴奋症状,抑制T4向T3的转化,控制心率,但与治疗一般甲亢不同的是应用剂量大,一般30~50mg,每6~8小时口服1次,或1mg经稀释后缓慢静脉注射,视需要可间歇给药3~5次。

(4)肾上腺糖皮质激素:

甲亢危象患者应用糖皮质激素也有抑制T4向T3转化的作用,同时还具有抗感染作用,可降低周围组织对甲状腺激素的反应,增强机体的应激能力。但在治疗时应注意剂量的掌握,开始时剂量较大,待症状患者应逐渐减量,一般静脉激素应用时间不超过1周。可给予氢化可的松100mg加入5%葡萄糖氯化钠注射液中静脉滴注,每6~8小时1次。

2﹒去除诱因,支持、对症治疗

去除诱因、积极治疗甲亢是预防危象发生的关键。应全程监护心、肾、脑功能,迅速纠正水、电解质和酸碱平衡紊乱,补充足够的葡萄糖、热量和多种维生素等。对症治疗包括供氧,防治感染,高热者给予物理降温,必要时可用中枢性解热药,如对乙酰氨基酚(扑热息痛)等。但应注意避免应用乙酰水杨酸类退热药(因可使FT3、FT4升高)。积极治疗各种并发症。待危象控制后,应根据病情选择适当的甲亢治疗方案,防止危象再次发生。

患者既有消化道的感染又同时存在肺部感染,全身症状重,且甲亢为高代谢消耗性疾病,所以应用了两种抗菌药,兼顾了球菌和杆菌,因患者病情重,抵抗力差,同时还应用了激素,应注意二重感染的问题,还应注意加强营养支持治疗,给予高热量、高维生素、高蛋白饮食。

3﹒保肝治疗

甲亢本身可以造成肝功能异常,抗甲状腺药物也可损伤肝功能,因此需要在治疗过程中严密监测肝功能变化。该患者已经出现了肝功能异常,故给予还原型谷胱甘肽保肝治疗。

还原型谷胱甘肽是人类细胞质中自然合成的一种肽,由谷氨酸、半胱氨酸和甘氨酸组成,含有巯基(-SH),广泛分布于机体各器官内,对维持细胞生物功能,保护细胞膜的完整性有着重要作用。它是甘油醛磷酸脱氢酶的辅基,又是乙二醛酶及丙糖脱氢酶的辅酶,参与体内三羧酸循环及糖代谢。还原型谷胱甘肽能激活多种酶,从而促进糖、脂肪及蛋白质代谢,并能影响细胞的代谢过程;它可通过转甲基及转丙氨基反应,保护肝脏的合成、解毒、灭活激素等功能,并促进胆酸代谢,有利于消化道吸收脂肪及脂溶性维生素。还原性谷胱甘肽参与体内氧化还原过程,对抗氧化剂对巯基的破坏保护细胞膜,同时可对抗自由基对重要脏器的损害。

4﹒减慢心室率

甲状腺激素能增加心肌细胞膜上β受体的数量和与儿茶酚胺的亲和力,促进心肌细胞肌质网的钙离子释放,可使心率加快,心肌收缩力增强,增加心排出量及心脏做功,故甲亢时可出现心动过速、房颤。普萘洛尔为非选择性竞争抑制肾上腺素β受体阻断剂,阻断心脏上的β1、β2受体,拮抗交感神经兴奋和儿茶酚胺作用,降低心脏的收缩力与收缩速度,同时抑制血管平滑肌收缩,降低心肌耗氧量,可使心率减慢,心肌收缩力减弱,心排出量下降,并可抑制外周血液中T4向T3转化。它虽然不能抑制人体内甲状腺素的合成,但却可以控制甲亢患者因交感神经兴奋所产生的症状,如心慌、心率加快、手颤、烦躁等。普萘洛尔的主要不良反应为心功能恶化、房室传导阻滞,对慢性支气管炎和肺部疾病患者,可诱发支气管痉挛,故伴哮喘或心功能不全的患者禁用。在治疗过程中,患者有心功能不全的表现:胸闷、气短,同时ECG示ptfv1阳性,BNP 312pg/ml ↑,故停用普萘洛尔,改为比索洛尔。

综上所述,对该例甲亢危象患者的治疗,不仅加强营养,应用抗生素控制感染,去除诱因,还应用了大剂量丙硫氧嘧啶、糖皮质激素、碘剂及β受体阻断剂,患者的病情很快得到了控制。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=306322, encodeId=602230632289, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94032318719, createdName=122457f6m94暂无昵称, createdTime=Mon Apr 16 12:15:05 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285359, encodeId=723628535900, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Feb 05 12:58:20 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284150, encodeId=9a6728415020, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Feb 01 10:46:13 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281507, encodeId=26f728150e5e, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Jan 24 08:49:47 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280126, encodeId=756328012636, content=甲亢危象救治措施.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jan 19 21:01:41 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280069, encodeId=4649280069e4, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Fri Jan 19 15:01:26 CST 2018, time=2018-01-19, status=1, ipAttribution=)]
    2018-04-16 122457f6m94暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=306322, encodeId=602230632289, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94032318719, createdName=122457f6m94暂无昵称, createdTime=Mon Apr 16 12:15:05 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285359, encodeId=723628535900, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Feb 05 12:58:20 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284150, encodeId=9a6728415020, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Feb 01 10:46:13 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281507, encodeId=26f728150e5e, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Jan 24 08:49:47 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280126, encodeId=756328012636, content=甲亢危象救治措施.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jan 19 21:01:41 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280069, encodeId=4649280069e4, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Fri Jan 19 15:01:26 CST 2018, time=2018-01-19, status=1, ipAttribution=)]
    2018-02-05 一个字-牛

    学习了谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=306322, encodeId=602230632289, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94032318719, createdName=122457f6m94暂无昵称, createdTime=Mon Apr 16 12:15:05 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285359, encodeId=723628535900, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Feb 05 12:58:20 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284150, encodeId=9a6728415020, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Feb 01 10:46:13 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281507, encodeId=26f728150e5e, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Jan 24 08:49:47 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280126, encodeId=756328012636, content=甲亢危象救治措施.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jan 19 21:01:41 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280069, encodeId=4649280069e4, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Fri Jan 19 15:01:26 CST 2018, time=2018-01-19, status=1, ipAttribution=)]
    2018-02-01 大爰

    学习了谢谢分享!!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=306322, encodeId=602230632289, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94032318719, createdName=122457f6m94暂无昵称, createdTime=Mon Apr 16 12:15:05 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285359, encodeId=723628535900, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Feb 05 12:58:20 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284150, encodeId=9a6728415020, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Feb 01 10:46:13 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281507, encodeId=26f728150e5e, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Jan 24 08:49:47 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280126, encodeId=756328012636, content=甲亢危象救治措施.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jan 19 21:01:41 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280069, encodeId=4649280069e4, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Fri Jan 19 15:01:26 CST 2018, time=2018-01-19, status=1, ipAttribution=)]
    2018-01-24 大爰

    学习了谢谢分享!!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=306322, encodeId=602230632289, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94032318719, createdName=122457f6m94暂无昵称, createdTime=Mon Apr 16 12:15:05 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285359, encodeId=723628535900, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Feb 05 12:58:20 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284150, encodeId=9a6728415020, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Feb 01 10:46:13 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281507, encodeId=26f728150e5e, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Jan 24 08:49:47 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280126, encodeId=756328012636, content=甲亢危象救治措施.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jan 19 21:01:41 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280069, encodeId=4649280069e4, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Fri Jan 19 15:01:26 CST 2018, time=2018-01-19, status=1, ipAttribution=)]
    2018-01-19 1e0f8808m18(暂无匿称)

    甲亢危象救治措施.学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=306322, encodeId=602230632289, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94032318719, createdName=122457f6m94暂无昵称, createdTime=Mon Apr 16 12:15:05 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285359, encodeId=723628535900, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon Feb 05 12:58:20 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284150, encodeId=9a6728415020, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Feb 01 10:46:13 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281507, encodeId=26f728150e5e, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Jan 24 08:49:47 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280126, encodeId=756328012636, content=甲亢危象救治措施.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jan 19 21:01:41 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280069, encodeId=4649280069e4, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Fri Jan 19 15:01:26 CST 2018, time=2018-01-19, status=1, ipAttribution=)]
    2018-01-19 情途末路

    学习了.获益匪浅!感谢分享

    0

Baidu
map
Baidu
map
Baidu
map